Akèy › Maladi Graves
Etid klinik pou Maladi Graves ap rekrite nan Etazini
15 etid pou Maladi Graves ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Miami, FL7 etid
- Dallas, TX7 etid
- Houston, TX6 etid
- San Antonio, TX6 etid
- Torrance, CA3 etid
- Havelock, NC3 etid
- Las Vegas, NV3 etid
- Kansas City, MO3 etid
- McKinney, TX3 etid
- Farmington Hills, MI3 etid
- Akron, OH3 etid
- Memphis, TN3 etid
- Doral, FL3 etid
- Asheville, NC3 etid
- Tucson, AZ3 etid
- Raleigh, NC3 etid
- El Paso, TX3 etid
- Hialeah, FL3 etid
- San Francisco, CA3 etid
Pa eta
- Arizona5 etid
- Florid8 etid
- Georgia5 etid
- Kalifòni9 etid
- Kansas4 etid
- Kentucky3 etid
- Maryland3 etid
- Michigan4 etid
- Missouri3 etid
- Nevada4 etid
- New York5 etid
- North Carolina8 etid
- Ohio4 etid
- Pennsylvania3 etid
- Tennessee4 etid
- Texas8 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Sep 30, 2026 · NCT07305818A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07570316Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 17, 2026 · NCT07661056A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 4, 2026 · NCT07722546Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07682896A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Aug 25, 2026 · NCT07018323A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Aug 25, 2026 · NCT06727604Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT07753603Preoperative Corticosteroids in Autoimmune Thyroid Disease
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT05435547Study of BHV-1300 in Graves' Disease
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Jul 31, 2026 · NCT06980649Telehealth Music Therapy for Adults With Endocrine Disorder and Depression
Ap rekrite
Laj 18 a 65 · Tout sèks · Mizajou Jul 30, 2026 · NCT07413874Evaluating an AI Tool for Detecting Thyrotoxic States
Ap rekriteEtid obsèvasyon
Laj 22 ak plis · Tout sèks · Mizajou Jun 1, 2026 · NCT07017907Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
Ap rekriteFaz 2
Laj 9 a 17 · Tout sèks · Mizajou Jan 27, 2026 · NCT07369063Personalized Treatment in Thyroid Disorders
Ap rekrite
Laj 21 a 65 · Tout sèks · Mizajou Oct 15, 2025 · NCT03517579The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Feb 23, 2024 · NCT06275373Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.